<DOC>
	<DOCNO>NCT02564237</DOCNO>
	<brief_summary>This single-centered trial group A streptococcal ( GAS ) vaccine , StreptAnova™ . The study design assess safety immunogenicity three dos ( 0 , 1 , 6 month ) one dosage ( 600 µg protein ) healthy adult 18 50 year age .</brief_summary>
	<brief_title>A Controlled Study Evaluate Safety Immunogenicity StreptAnova™ Healthy Adults</brief_title>
	<detailed_description>This single-centered trial group A streptococcal ( GAS ) vaccine , StreptAnova™ , perform Canada . It randomize , observer-blinded , comparator control . The study design assess safety immunogenicity three dos ( 0 , 1 , 6 month ) one dosage ( 600 µg protein ) healthy adult 18 50 year age . A comparator vaccine include 2:1 ratio ( StreptAnova™ comparator ) . Assignment StreptAnova™ comparator vaccine randomize observer-blinded . Three ( 3 ) 0.6 mL dos ( 600 µg protein ) StreptAnova™ 0.5 mL dos comparator administered day 0 , 30 180 ( N= 30 StreptAnova™ , 15 comparator ) ; subject receive three dos treatment . Forty-five subject enrol . At vaccine dose , detailed safety data collect first 15 randomized subject seven day administration use determine whether proceed immunize 30 remain subject . Detailed safety data collect remain 30 randomized subject seven day administration use determine whether proceed immunize first 15 randomized subject next dose . Treatments follow standard clinical parameter evaluate safety biologic/vaccine product include standardized method local systemic vaccine reaction , repeat vital sign physical examination , 12-month follow-up ( 6 month post-dose 3 ) adverse event concomitant medication change , monitor clinical laboratory value clinically indicate .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female healthy adult age 18 50 year inclusive ; Good general health determine screen evaluation great 42 day first immunization ; For woman childbearing age , use adequate birth control enrollment 180 day last injection ; Written inform consent , read consent form adequate opportunity discus study investigator qualify designee . Presence febrile illness know suspected acute illness day first immunization ; Any chronic illness , whether active treatment require ; Any immunodeficiency ( congenital acquire ) ; Any history cardiac pathology ( acquire severe/persistent congenital ) ; Any history congenital malformation syndrome associate congenital heart disease ( syndrome complex , e.g . VATER association ; chromosomal disorder , e.g . Down 's Syndrome ; teratogenic agent , e.g . fetal alcohol syndrome ; others , e.g . Noonan 's ) ; Any history clinical manifestation autoimmune systemic disease ( inflammatory disorder , e.g . JRA , SLE , Kawasaki disease ; inborn error metabolism , e.g . Fabry ; connective tissue disorder , e.g . Marfan syndrome ; neuromuscular disorder , e.g . Friedreich ataxia ; endocrinemetabolic disorder , e.g . hypothyroidism ; hematologic disorder , e.g . sickle cell anemia ) ; Any history acute rheumatic fever ( ARF ) , poststreptococcal glomerulonephritis ( PSGN ) , undiagnosed acute selflimiting polyarthritis ( swell , heat , redness tenderness pain limitation motion &gt; 2 joint ) , chorea ( purposeless , involuntary rapid movement trunk and/or extremity ) ; Any previous echocardiogram suggestive cardiac pathology ; Any immediate family history ( parent , sibling ) ARF , PSGN , selflimiting polyarthritis , chorea , collagenvascular disease Lupus Sjögren 's syndrome ; Receipt systemic glucocorticoid ( dose ≥ 20 mg/day prednisone equivalent ) within one month , cytotoxic immunosuppressive drug within six month ; Receipt investigational drug within six month , prior participation clinical trial group A streptococcal vaccine ; Receipt blood product immunoglobulin ( IVIg IMIg ) within three ( 3 ) month study entry/baseline serologic evaluation ; Any physical finding suggestive acute chronic illness ; History receive Adriamycin chemotherapy ; Use follow diet pill : fenfluramine , phentermine , dexfenfluramins ( also know Pondimin , Redux , Adipex , Fastin ) ; History sensitivity component study vaccine ; Evidence tissue crossreactive antibody human heart , joint cartilage , kidney , cerebral cortex basal ganglion indirect fluorescent antibody assay prevaccination screening ; Repeatable clinical laboratory abnormality ( blood urine ) , define lab normal range . To exclude transient abnormality , investigator may repeat test twice , repeat test normal , subject may enrol ; Echocardiographic find valvular dysfunction ( stenosis , leaflet thickening nodule , restrict leaflet mobility , prolapse ) , LV dysfunction , atrial ventricular enlargement , mild great mitral regurgitation aortic insufficiency , moderate great tricuspid regurgitation pulmonic insufficiency , pericardial effusion , cardiac pathology identify echocardiologist* ; Receipt vaccine within 2 week Dose 1 ; Clinically significant abnormality screen electrocardiogram* Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Group A streptococcal</keyword>
</DOC>